Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence
- PMID: 21343373
- PMCID: PMC3059497
- DOI: 10.1158/1078-0432.CCR-10-0881
Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence
Abstract
Purpose: Genome-wide association studies (GWAS) have identified multiple novel prostate cancer predisposition loci. Whether these common genetic variants are associated with incident metastatic prostate cancer or with recurrence after surgical treatment for clinically localized prostate cancer is uncertain.
Experimental design: Twelve single nucleotide polymorphisms (SNPs) were selected for study in relation to prostate metastatic cancer and recurrence, based on their genome-wide association with prostate cancer in the Cancer Genetic Markers of Susceptibility (CGEMS). To assess risk for metastatic disease, we compared genotypes for the 12 SNPs by logistic regression of 470 incident metastatic prostate cancer cases and 1,945 controls in 3 case-control studies. To assess the relationship of these SNPs to risk for prostate cancer recurrence, we used Cox regression in a cohort of 1,412 men treated for localized prostate cancer, including 328 recurrences, and used logistic regression in a case-case study, comparing 450 recurrent versus 450 nonrecurrent prostate cancer cases. Study-specific relative risks (RRs) for risk of metastatic disease and recurrence were summarized using meta-analysis, with inverse variance weights.
Results: MSMB rs10993994 (per variant allele summary RR = 1.24, 95% CI = 1.05-1.48), 8q24 rs4242382 (RR = 1.40, 95% CI = 1.13-1.75), and 8q24 rs6983267 (RR = 0.67, 95% CI = 0.50-0.89) were associated with risk for metastatic prostate cancer. None of the 12 SNPs was associated with prostate cancer recurrence.
Conclusions: SNPs in MSMB and 8q24 which predispose to prostate cancer overall are associated with risk for metastatic prostate cancer, the most lethal form of this disease. SNPs predictive of prostate cancer recurrence were not identified, among the predisposition SNPs. GWAS specific to these 2 phenotypes may identify additional phenotype-specific genetic determinants.
©2011 AACR.
Similar articles
-
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans.J Natl Cancer Inst. 2007 Oct 17;99(20):1525-33. doi: 10.1093/jnci/djm169. Epub 2007 Oct 9. J Natl Cancer Inst. 2007. PMID: 17925536
-
Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features.Clin Cancer Res. 2009 May 1;15(9):3231-7. doi: 10.1158/1078-0432.CCR-08-2190. Epub 2009 Apr 14. Clin Cancer Res. 2009. PMID: 19366831 Free PMC article.
-
Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy.Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3068-74. doi: 10.1158/1055-9965.EPI-09-0665. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19900942
-
MSMB gene rs10993994 polymorphism increases the risk of prostate cancer.Oncotarget. 2017 Apr 25;8(17):28494-28501. doi: 10.18632/oncotarget.15312. Oncotarget. 2017. PMID: 28212531 Free PMC article.
-
8q24 rs4242382 polymorphism is a risk factor for prostate cancer among multi-ethnic populations: evidence from clinical detection in China and a meta-analysis.Asian Pac J Cancer Prev. 2014;15(19):8311-7. doi: 10.7314/apjcp.2014.15.19.8311. Asian Pac J Cancer Prev. 2014. PMID: 25339022 Review.
Cited by
-
The rs10993994 in the proximal MSMB promoter region is a functional polymorphism in Asian Indian subjects.Springerplus. 2015 Jul 28;4:380. doi: 10.1186/s40064-015-1164-7. eCollection 2015. Springerplus. 2015. PMID: 26240778 Free PMC article.
-
Effects of Caspase 9 Gene Polymorphism in Patients with Prostate Cancer.In Vivo. 2017 Mar-Apr;31(2):205-208. doi: 10.21873/invivo.11046. In Vivo. 2017. PMID: 28358701 Free PMC article.
-
Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer.Oncotarget. 2018 Feb 5;9(16):12812-12824. doi: 10.18632/oncotarget.24400. eCollection 2018 Feb 27. Oncotarget. 2018. PMID: 29560112 Free PMC article.
-
Genome-wide association studies on prostate cancer: the end or the beginning?Protein Cell. 2013 Sep;4(9):677-86. doi: 10.1007/s13238-013-3055-4. Epub 2013 Aug 27. Protein Cell. 2013. PMID: 23982739 Free PMC article. Review.
-
Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases.Hum Genet. 2015 Apr;134(4):439-50. doi: 10.1007/s00439-015-1534-9. Epub 2015 Feb 26. Hum Genet. 2015. PMID: 25715684 Free PMC article.
References
-
- Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF, Hoover R, Hayes RB, Hunter DJ, Chanock SJ. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008;40:310–315. - PubMed
-
- Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF, Jr, Hoover R, Hunter DJ, Chanock SJ, Thomas G. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007;39:645–649. - PubMed
-
- Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier JB, Sainz J, Jakobsdottir M, Kostic J, Magnusdottir DN, Ghosh S, Agnarsson K, Birgisdottir B, Le Roux L, Olafsdottir A, Blondal T, Andresdottir M, Gretarsdottir OS, Bergthorsson JT, Gudbjartsson D, Gylfason A, Thorleifsson G, Manolescu A, Kristjansson K, Geirsson G, Isaksson H, Douglas J, Johansson JE, Balter K, Wiklund F, Montie JE, Yu X, Suarez BK, Ober C, Cooney KA, Gronberg H, Catalona WJ, Einarsson GV, Barkardottir RB, Gulcher JR, Kong A, Thorsteinsdottir U, Stefansson K. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006;38:652–658. - PubMed
-
- Eeles RA, Kote-Jarai Z, Giles GG, Olama AAA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008;40:316–321. - PubMed
-
- Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, Waliszewska A, Penney K, Steen RG, Ardlie K, John EM, Oakley-Girvan I, Whittemore AS, Cooney KA, Ingles SA, Altshuler D, Henderson BE, Reich D. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A. 2006;103:14068–14073. - PMC - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical